4.A History and development of the company The information set forth under the heading: • “About GSK” on page 317; • “Head Office and Registered Office” on the outside back cover; • “Note 41 – Acquisitions and disposals” on pages 237 to 241; and • “Demerger and Share Consolidation” on page 296 of the GSK Annual Report 2022 is incorporated herein by reference. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The address of that site is http://www.sec.gov. GSK’s Internet address is gsk.com. 4.B Business overview • See Item 3.D “Risk factors” above. In addition, the information set forth under the headings: • “Ahead Together” on page 1 (excluding the paragraph under the heading “We’re confident in our future”) • “Chair’s statement” on pages 4 and 5 (excluding (i) the seventh paragraph on page 4 and (ii) the first paragraph under “Targets and governance” on page 5); • “CEO’s statement” on pages 6 and 7 (excluding the heading “Strong 2022 performance increases confidence in delivering growth through 2026 and beyond” and the paragraphs thereunder on page 6); • “Business model” on pages 8 and 9 (excluding (i) the second paragraph under “Performance” on page 9 and (ii) the last paragraph at the bottom of page 9); • “Our culture and people” on pages 10 and 11; • “Our external environment” on pages 12 to 14; • “Research and Development” on pages 15 to 28; • “Performance: Vaccines” on pages 29 to 32; • “Performance: Specialty Medicines” on pages 33 to 37 (excluding the fifth bullet under “Drivers of growth across the portfolio” on page 35); • “Performance: General Medicines” on pages 38 to 40; • “Responsible business” on pages 41 to 50 (excluding the second paragraph under the heading “2022 ESG Performance Rating” on page 42); • “Climate-related financial disclosures” on pages 55 to 63 (excluding the third sentence in Note 2 to the table on page 62); • “Note 6 – Turnover and segment information” on pages 195 to 197; • “Note 41 – Acquisitions and disposals” on pages 237 to 241; • “Pharmaceutical products, competition and intellectual property” on pages 282 and 283; and • “Vaccines products, competition and intellectual property” on page 284 of the GSK Annual Report 2022 is incorporated herein by reference. 4.C Organizational structure The information set forth under the headings: • “Note 46 – Principal Group companies” on page 264; and • “Group companies” on pages 307 to 314 of the GSK Annual Report 2022 is incorporated herein by reference. 4.D Property, plant and equipment The information set forth under the heading “Property, plant and equipment” under “Financial position and resources” in Item 5.A of this annual report on Form 20-F is incorporated herein by reference. The information set forth under the headings: • “PP&E, intangible asset and goodwill impairment by segment” and “PP&E and intangible asset impairment reversals by segment” within “Note 6 – Turnover and segment information” on page 197; and • “Note 17 – Property, plant and equipment” on pages 208 and 209 of the GSK Annual Report 2022 is incorporated herein by reference.